6J3O
Crystal structure of the human PCAF bromodomain in complex with compound 12
Summary for 6J3O
| Entry DOI | 10.2210/pdb6j3o/pdb |
| Descriptor | Histone acetyltransferase KAT2B, 3-methyl-2-[[(3~{R})-1-methylpiperidin-3-yl]amino]-5~{H}-pyrrolo[3,2-d]pyrimidin-4-one (3 entities in total) |
| Functional Keywords | crystal structure of the human pcaf bromodomain in complex with compound 12, transferase |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 2 |
| Total formula weight | 33810.74 |
| Authors | Huang, L.Y.,Li, H.,Li, L.L.,Niu, L.,Seupel, R.,Wu, C.Y.,Li, G.B.,Yu, Y.M.,Brennan, P.E.,Yang, S.Y. (deposition date: 2019-01-05, release date: 2019-05-01, Last modification date: 2023-11-22) |
| Primary citation | Huang, L.,Li, H.,Li, L.,Niu, L.,Seupel, R.,Wu, C.,Cheng, W.,Chen, C.,Ding, B.,Brennan, P.E.,Yang, S. Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain. J.Med.Chem., 62:4526-4542, 2019 Cited by PubMed Abstract: Herein, we report the discovery of a series of new P300/CBP-associated factor (PCAF) bromodomain (BRD) inhibitors, which were obtained through a hit discovery process and subsequent structure-based optimization and structure-activity relationship analyses toward a retrieved hit compound (12). Among these inhibitors, ( R, R)-36n is the most potent one with an IC of 7 nM in homogeneous time-resolved fluorescence assay and a K of 78 nM in isothermal titration calorimetry assay. This compound also exhibited activity against GCN5 and FALZ, but weak or no activity against other 29 BRD proteins and 422 kinases, indicating considerable selectivity. X-ray cocrystal structure analysis revealed the molecular interaction mode and the precise stereochemistry required for bioactivity. Cellular activity, preliminary RNA-seq analysis, and pharmacokinetic properties were also examined for this compound. Collectively, this study provides a versatile tool molecule to explore molecular mechanisms of PCAF BRD regulation and also offers a new lead compound for drug discovery targeting PCAF. PubMed: 30998845DOI: 10.1021/acs.jmedchem.9b00096 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.11 Å) |
Structure validation
Download full validation report






